Published in Clin J Am Soc Nephrol on May 19, 2011
An association between time-varying serum alkaline phosphatase concentrations and mortality rate in patients undergoing peritoneal dialysis: a five-year cohort study. Sci Rep (2017) 1.39
Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int (2014) 1.00
Alkaline phosphatase and mortality in patients on peritoneal dialysis. Clin J Am Soc Nephrol (2014) 0.95
Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis (2013) 0.93
Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int (2015) 0.89
Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant (2013) 0.89
Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study. Am J Kidney Dis (2013) 0.88
Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients. Medicine (Baltimore) (2014) 0.85
Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting. Am J Kidney Dis (2014) 0.84
Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. BMJ Open (2014) 0.82
Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol (2014) 0.78
Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol (2016) 0.78
Bone mineral metabolism parameters and urinary albumin excretion in a representative US population sample. PLoS One (2014) 0.77
Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int (2012) 0.77
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Can J Kidney Health Dis (2015) 0.76
Oxidative Stress as Estimated by Gamma-Glutamyl Transferase Levels Amplifies the Alkaline Phosphatase-Dependent Risk for Mortality in ESKD Patients on Dialysis. Oxid Med Cell Longev (2016) 0.75
Does PTH offer additive value to ALP measurement in assessing CKD-MBD? Perit Dial Int (2014) 0.75
Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol (2017) 0.75
Elevated serum alkaline phosphatase and cardiovascular or all-cause mortality risk in dialysis patients: A meta-analysis. Sci Rep (2017) 0.75
Circulating markers of bone turnover. J Nephrol (2017) 0.75
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med (2008) 7.21
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest (2003) 3.71
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant (2003) 2.95
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant (2007) 2.91
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis (2011) 2.88
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85
Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol (2010) 2.82
Newborn hearing screening vs later hearing screening and developmental outcomes in children with permanent childhood hearing impairment. JAMA (2010) 2.80
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int (2005) 2.78
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73
Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant (2009) 2.69
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab (2008) 2.60
Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant (2007) 2.53
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 2.51
Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes (2012) 2.43
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis (2004) 2.40
A regression model with unexplained residuals was preferred in the analysis of the fetal origins of adult diseases hypothesis. J Clin Epidemiol (2005) 2.39
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int (2008) 2.36
The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology (2012) 2.30
Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ (2006) 2.29
Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation (2006) 2.27
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2007) 2.23
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
Time-dependent reasons for peritoneal dialysis technique failure and mortality. Perit Dial Int (2010) 2.17
Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr (2011) 2.16
Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. J Am Soc Nephrol (2005) 2.16
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab (2010) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int (2002) 2.12
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis (2011) 2.01
Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant (2004) 1.99
Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int (2009) 1.96
When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant (2013) 1.95
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant (2010) 1.90
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol (2009) 1.88
A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab (2004) 1.87
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int (2003) 1.87
Tuning research competences for Bologna three cycles in medicine: report of a MEDINE2 European consensus survey. Perspect Med Educ (2013) 1.87
Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int (2004) 1.86
Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol (2009) 1.86
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
Social support predicts survival in dialysis patients. Nephrol Dial Transplant (2006) 1.84
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant (2010) 1.83
Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J (2010) 1.82
Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int (2010) 1.82
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81